Range Low Price High Price Comment
30 days $1.91 $2.71 Monday, 29th Apr 2024 CANF stock ended at $1.97. This is 0.505% less than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 2.68% from a day low at $1.97 to a day high of $2.02.
90 days $1.91 $2.71
52 weeks $1.71 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Jan 29, 2016 $2.17 $2.25 $2.13 $2.20 57 000
Jan 28, 2016 $2.19 $2.22 $2.12 $2.20 49 300
Jan 27, 2016 $2.14 $2.23 $2.14 $2.19 76 400
Jan 26, 2016 $2.15 $2.25 $2.10 $2.23 98 300
Jan 25, 2016 $2.19 $2.25 $2.16 $2.17 118 800
Jan 22, 2016 $2.15 $2.28 $2.15 $2.16 151 500
Jan 21, 2016 $1.91 $2.17 $1.91 $2.14 195 600
Jan 20, 2016 $1.99 $2.01 $1.88 $2.00 360 500
Jan 19, 2016 $2.34 $2.34 $2.01 $2.04 524 500
Jan 15, 2016 $2.03 $2.03 $1.85 $1.99 258 600
Jan 14, 2016 $2.16 $2.24 $2.00 $2.11 380 200
Jan 13, 2016 $2.36 $2.48 $2.21 $2.29 202 600
Jan 12, 2016 $2.41 $2.50 $2.29 $2.40 165 300
Jan 11, 2016 $2.64 $2.64 $2.28 $2.40 221 900
Jan 08, 2016 $2.64 $2.67 $2.35 $2.40 296 200
Jan 07, 2016 $2.79 $2.79 $2.50 $2.50 385 200
Jan 06, 2016 $2.87 $2.87 $2.77 $2.80 193 300
Jan 05, 2016 $3.05 $3.05 $2.81 $2.85 233 900
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT